Tags

Type your tag names separated by a space and hit enter

The "MESACA" study: methylsulfonylmethane and boswellic acids in the treatment of gonarthrosis.
Adv Ther. 2011 Oct; 28(10):894-906.AT

Abstract

INTRODUCTION

Osteoarthritis is a chronic rheumatoid disease mediated by metalloproteinases and inflammatory cytokines. Methylsulfonylmethane (MSM) and boswellic acids (BA) each show promise in the treatment of inflammatory processes, but the efficacy of combined treatment with these substances in the treatment of arthritis has not yet been studied.

METHODS

In this prospective randomized clinical trial, MESACA (for "methylsulfonylmethane and boswellic acids in the treatment of knee arthritis"), 60 subjects affected by arthritis of the knee were randomly assigned to an experimental group treated for 60 days with 5 g of MSM and 7.2 mg of BA daily, or a control group which was administered a placebo. At 2 and 6 months follow-up (FU), the efficacy of combined treatment with these two dietary supplements was assessed using the visual analog pain scale (VAS) and the Lequesne index (LI) for joint function, as well as monitoring the use of anti-inflammatory drugs (nonsteroidal anti-inflammatory drugs and anti-cyclooxygenase-2).

RESULTS

Pain, assessed with the VAS scale, was worse in the group treated with MSM and BA as compared with the placebo group at 2 months FU (3.8 vs. 2.7; P=0.04), whereas no difference between the two groups was observed at 6 months FU (2.7 vs. 3.6; P=0.2). No statistically significant differences were found in the LI between the two groups at either FU (2 months: 4.8 vs. 4.2; P=0.51; 6 months: 4.4 vs. 4.5; P=0.91). By contrast, a statistically significant difference in patients need for anti-inflammatory drugs was seen in the experimental as compared to the placebo group, even by 2 months FU (0.2 vs. 0.6 tablets/day; P<0.0001), that persisted up to the end of the study (0.1 vs. 0.6 tablets/day; P<0.0001).

CONCLUSIONS

Although the combined administration of MSM and BA in the treatment of gonarthrosis was not shown to be more efficacious than placebo in the management of the clinical and functional picture, it significantly reduced patients need for anti-inflammatory drugs.

Authors+Show Affiliations

Department of Clinical Methodology and Medical-Surgical Technologies-Orthopaedics Section, University General Hospital, Bari, Italy. angelanotarnicola@yahoo.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

21986780

Citation

Notarnicola, Angela, et al. "The "MESACA" Study: Methylsulfonylmethane and Boswellic Acids in the Treatment of Gonarthrosis." Advances in Therapy, vol. 28, no. 10, 2011, pp. 894-906.
Notarnicola A, Tafuri S, Fusaro L, et al. The "MESACA" study: methylsulfonylmethane and boswellic acids in the treatment of gonarthrosis. Adv Ther. 2011;28(10):894-906.
Notarnicola, A., Tafuri, S., Fusaro, L., Moretti, L., Pesce, V., & Moretti, B. (2011). The "MESACA" study: methylsulfonylmethane and boswellic acids in the treatment of gonarthrosis. Advances in Therapy, 28(10), 894-906. https://doi.org/10.1007/s12325-011-0068-3
Notarnicola A, et al. The "MESACA" Study: Methylsulfonylmethane and Boswellic Acids in the Treatment of Gonarthrosis. Adv Ther. 2011;28(10):894-906. PubMed PMID: 21986780.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The "MESACA" study: methylsulfonylmethane and boswellic acids in the treatment of gonarthrosis. AU - Notarnicola,Angela, AU - Tafuri,Silvio, AU - Fusaro,Lucrezia, AU - Moretti,Lorenzo, AU - Pesce,Vito, AU - Moretti,Biagio, Y1 - 2011/10/07/ PY - 2011/07/26/received PY - 2011/10/12/entrez PY - 2011/10/12/pubmed PY - 2012/3/3/medline SP - 894 EP - 906 JF - Advances in therapy JO - Adv Ther VL - 28 IS - 10 N2 - INTRODUCTION: Osteoarthritis is a chronic rheumatoid disease mediated by metalloproteinases and inflammatory cytokines. Methylsulfonylmethane (MSM) and boswellic acids (BA) each show promise in the treatment of inflammatory processes, but the efficacy of combined treatment with these substances in the treatment of arthritis has not yet been studied. METHODS: In this prospective randomized clinical trial, MESACA (for "methylsulfonylmethane and boswellic acids in the treatment of knee arthritis"), 60 subjects affected by arthritis of the knee were randomly assigned to an experimental group treated for 60 days with 5 g of MSM and 7.2 mg of BA daily, or a control group which was administered a placebo. At 2 and 6 months follow-up (FU), the efficacy of combined treatment with these two dietary supplements was assessed using the visual analog pain scale (VAS) and the Lequesne index (LI) for joint function, as well as monitoring the use of anti-inflammatory drugs (nonsteroidal anti-inflammatory drugs and anti-cyclooxygenase-2). RESULTS: Pain, assessed with the VAS scale, was worse in the group treated with MSM and BA as compared with the placebo group at 2 months FU (3.8 vs. 2.7; P=0.04), whereas no difference between the two groups was observed at 6 months FU (2.7 vs. 3.6; P=0.2). No statistically significant differences were found in the LI between the two groups at either FU (2 months: 4.8 vs. 4.2; P=0.51; 6 months: 4.4 vs. 4.5; P=0.91). By contrast, a statistically significant difference in patients need for anti-inflammatory drugs was seen in the experimental as compared to the placebo group, even by 2 months FU (0.2 vs. 0.6 tablets/day; P<0.0001), that persisted up to the end of the study (0.1 vs. 0.6 tablets/day; P<0.0001). CONCLUSIONS: Although the combined administration of MSM and BA in the treatment of gonarthrosis was not shown to be more efficacious than placebo in the management of the clinical and functional picture, it significantly reduced patients need for anti-inflammatory drugs. SN - 1865-8652 UR - https://www.unboundmedicine.com/medline/citation/21986780/The_"MESACA"_study:_methylsulfonylmethane_and_boswellic_acids_in_the_treatment_of_gonarthrosis_ L2 - https://dx.doi.org/10.1007/s12325-011-0068-3 DB - PRIME DP - Unbound Medicine ER -